Lost Money on Intellia Therapeutics, Inc.(NTLA)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
Portfolio Pulse from
Levi & Korsinsky law firm has filed a class action securities lawsuit against Intellia Therapeutics (NTLA) alleging securities fraud between July 30, 2024 and January 8, 2025. The lawsuit claims the company misled investors about its NTLA-3001 study for alpha-1 antitrypsin deficiency, failing to disclose declining demand for viral-based editing. On January 9, 2025, Intellia announced halting the research and reducing workforce by 27%, causing its stock price to drop from $12.02 to $10.20.
April 10, 2025 | 10:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Intellia Therapeutics announced discontinuation of NTLA-3001 research and 27% workforce reduction, leading to potential investor concerns and stock price volatility.
The lawsuit and company's announcement of research discontinuation and workforce reduction suggest significant operational challenges, likely to negatively impact investor sentiment and stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100